Quarterly ResultAug 5, 2026, 04:17 PM
GoodRx Q2 Revenue $200.4M; Raises FY26 Guidance
AI Summary
GoodRx Holdings, Inc. reported Q2 2026 revenue of $200.4 million, a 1% decrease year-over-year, with net income at $8.5 million. Despite a decline in prescription transactions revenue, the company saw strong growth in its strategic areas, with Pharma Direct revenue increasing 76% and subscription revenue rising 39%. Management raised its full-year 2026 guidance for both revenue and Adjusted EBITDA, citing strong first-half performance and progress in scaling Pharma Direct and subscriptions.
Key Highlights
- Q2 2026 Revenue was $200.4 million, a 1% decrease year-over-year.
- Pharma Direct revenue increased 76% to $61.6 million in Q2 2026.
- Subscription revenue increased 39% to $28.5 million in Q2 2026.
- Net income for Q2 2026 was $8.5 million, down from $12.8 million year-over-year.
- Adjusted EBITDA for Q2 2026 was $63.7 million, down from $69.4 million year-over-year.
- Net cash provided by operating activities was $80.8 million, up from $49.6 million year-over-year.
- Full-year 2026 revenue guidance raised to $790 - $805 million.
- Full-year 2026 Adjusted EBITDA guidance raised to $240 - $250 million.
Price Impact
More from GDRX